Biogen's Alzheimer's drug Aduhelm faces EU rejection
Biogen hasn't won support to have its Alzheimer's treatment Aduhelm marketed in the EU, as the drug has received a negative opinion in a trend vote from the EMA's expert committee, the CHMP. The formal rejection of Biogen's marketing authorization application is expected in December.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
The controversial approval of Biogen's drug Aduhelm (aducanumab) in the US hasn't been followed by a corresponding approval in the EU, the company itself reports in a press release on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP approves 11 new drugs, rejects one
For subscribers
